|
|
|
|
|
非在研适应症- |
最高研发阶段临床1/2期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors
TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.
A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK201.
一项评估注射用ALK201在成人晚期实体瘤研究参与者中的安全性、耐受性、药代动力学和抗肿瘤活性的开放、多中心、首次人体I/II期临床研究
本研究旨在晚期实体瘤患者中评价ALK201 的安全性、耐受性、药代动力学（PK）和初步抗肿瘤活性。
100 项与 上海安领科生物医药有限公司 相关的临床结果
0 项与 上海安领科生物医药有限公司 相关的专利（医药）
100 项与 上海安领科生物医药有限公司 相关的药物交易
100 项与 上海安领科生物医药有限公司 相关的转化医学
